Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: high prevalence of occult hepatitis B and F3 subgenotype dominance.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science

Genotype*; HIV Infections/*complications ; Hepatitis B/*virology ; Hepatitis B virus/*genetics; Adult ; Colombia/epidemiology ; Cross-Sectional Studies ; Female ; Hepatitis B/complications ; Humans ; Male ; Middle Aged ; Molecular Sequence Data ; Prevalence ; Risk Factors

Introduction: Chronic hepatitis B virus (HBV) infection is an increasing cause of morbidity and mortality in human immunodeficiency virus (HIV)-infected individuals. HIV-positive patients are commonly co-infected with HBV due to shared routes of transmission.
Objectives: Our aim was to determine the risk factors, prevalence, genotypes, and mutations of the Surface S gene of HBV, and occult hepatitis B infection (OBI) among patients infected with HIV in a northeastern Colombian city.
Methods: A cross-sectional study was conducted with 275 HIV-positive patients attending an outpatient clinic in Bucaramanga, Colombia during 2009-2010. Blood samples were collected and screened for serological markers of HBV (anti-HBs, anti-HBc and HBsAg) through ELISA assay. Regardless of their serological profile, all samples were tested for the HBV S gene by nested-PCR and HBV genotypes were determined by phylogenetic inference. Clinical records were used to examine demographic, clinical, virological, immunological and antiretroviral therapy (ART) variables of HIV infection.
Results: Participants were on average 37±11 years old and 65.1% male. The prevalence of HIV-HBV coinfection was 12% (95%CI 8.4-16.4) of which 3.3% had active HBV infection and 8.7% OBI. The prevalence of HIV-HBV coinfection was associated with AIDS stage and ART treatment. Sequence analysis identified genotype F, subgenotype F3 in 93.8% of patients and genotype A in 6.2% of patients. A C149R mutation, which may have resulted from failure in HBsAg detection, was found in one patient with OBI.
Conclusions: The present study found a high prevalence of HIV-HBV coinfection with an incidence of OBI 2.6-fold higher compared to active HBV infection. These findings suggest including HBV DNA testing to detect OBI in addition to screening for HBV serological markers in HIV patients.

J Med Virol. 2007 Oct;79(10):1464-71. (PMID: 17705185)
Infect Genet Evol. 2011 Jan;11(1):103-8. (PMID: 20951841)
Mem Inst Oswaldo Cruz. 2006 Sep;101(6):655-60. (PMID: 17072479)
Rev Inst Med Trop Sao Paulo. 2000 Mar-Apr;42(2):81-5. (PMID: 10810322)
Ann Intern Med. 1984 Dec;101(6):795-7. (PMID: 6497194)
Dig Dis Sci. 2010 Dec;55(12):3328-35. (PMID: 20927592)
World J Hepatol. 2010 Feb 27;2(2):65-73. (PMID: 21160975)
J Gen Virol. 2008 Feb;89(Pt 2):409-418. (PMID: 18198371)
Liver Int. 2012 Feb;32(2):231-40. (PMID: 21745272)
J Clin Virol. 2001 Jun;21(3):229-37. (PMID: 11397659)
Semin Immunopathol. 2013 Jan;35(1):39-52. (PMID: 22829332)
J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):315-20. (PMID: 17159655)
J Mol Evol. 1980 Dec;16(2):111-20. (PMID: 7463489)
BMC Infect Dis. 2006 Feb 25;6:34. (PMID: 16504137)
Ann Hepatol. 2006 Jan-Mar;5(1):34-40. (PMID: 16531963)
BMC Infect Dis. 2010 Mar 07;10:53. (PMID: 20205948)
J Med Virol. 2006 Jan;78(1):24-36. (PMID: 16299725)
Mem Inst Oswaldo Cruz. 2000 Mar-Apr;95(2):243-5. (PMID: 10733747)
J Infect Dis. 2012 Jan 15;205(2):185-93. (PMID: 22147794)
J Hepatol. 2006;44(1 Suppl):S6-9. (PMID: 16352363)
J Clin Virol. 2006 Jan;35(1):14-20. (PMID: 15916918)
PLoS One. 2011 Apr 29;6(4):e18888. (PMID: 21559488)
Clin Liver Dis. 2010 Feb;14(1):1-21, vii. (PMID: 20123436)
Rev Inst Med Trop Sao Paulo. 2006 Nov-Dec;48(6):321-6. (PMID: 17221128)
J Med Virol. 2009 Mar;81(3):441-5. (PMID: 19152397)
PLoS One. 2013;8(3):e59346. (PMID: 23527168)
Mol Biol Evol. 1987 Jul;4(4):406-25. (PMID: 3447015)
Rev Soc Bras Med Trop. 2004 Sep-Oct;37(5):391-5. (PMID: 15361955)
J Acquir Immune Defic Syndr. 2010 Jun;54(2):122-8. (PMID: 20386111)
J Trop Med. 2014;2014:796121. (PMID: 24868208)
J Hepatol. 2008 Oct;49(4):652-7. (PMID: 18715666)
AIDS. 2011 Jan 2;25(1):73-9. (PMID: 21076274)
HIV Med. 2007 May;8(4):251-8. (PMID: 17461853)
Virology. 2013 Feb 5;436(1):134-42. (PMID: 23228859)
Rev Soc Bras Med Trop. 2006 Nov-Dec;39(6):519-22. (PMID: 17308694)
Mol Biol Evol. 2013 Dec;30(12):2725-9. (PMID: 24132122)
Hepat Res Treat. 2013;2013:259148. (PMID: 23533738)
AIDS Res Hum Retroviruses. 2007 Apr;23(4):525-31. (PMID: 17506609)
Rev Saude Publica. 2007 Dec;41 Suppl 2:57-63. (PMID: 18094787)
Virus Genes. 2012 Jun;44(3):382-7. (PMID: 22274739)
J Clin Virol. 2007 Jan;38(1):83-6. (PMID: 17134939)
J Viral Hepat. 2009 Jun;16(6):437-43. (PMID: 19226331)
Clin Microbiol Rev. 2012 Jan;25(1):142-63. (PMID: 22232374)
World J Hepatol. 2012 Jul 27;4(7):218-23. (PMID: 22855697)
Hepatology. 2013 Aug;58(2):538-45. (PMID: 23505059)
J Virol. 2013 Feb;87(4):2352-7. (PMID: 23221548)

GENBANK KM583833; KM583834; KM583835; KM583836; KM583837; KM583838; KM583839; KM583840; KM583841; KM583842; KM583843; KM583844; KM583845; KM583846; KM583847

Date Created: 20141203 Date Completed: 20160108 Latest Revision: 20220330

20240513

PMC4252145

10.1371/journal.pone.0114272

25462190